The markets might be in turmoil, but spare a thought for the current woes at biotech Amarin (AMRN). Over the past 7 trading sessions, shares have retreated by 44% as investors charged to the exit doors following a botched date in court.Last week, an appeals court rejected Amarin’s appeal concerning a lost patent court case against generic drug makers Hikma Pharmaceuticals and Dr. Reddy’s, who are seeking to bring to market their own versions of Amarin’s high triglyceride treatment Vascepa.As Vascepa is Amarin’s only product, the ruling has obviously spooked investors, who are concerned the treatment’s vast commercial opportunity is …read more
Source:: Yahoo Finance
